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Demographic details
Fifty patients underwent a heart transplant between 2017 and 2018. The age ranged from 21 to 66 years, and there were 45 males and 10 females. All patients were Class III and IV (25 were Class IV and 4 were on an assist device). Pulmonary vascular resistance ranged from 0.5 to 6.9 wood units. (Testing if required was done with injection milrinone or nitric oxide). The patient follow-up data up to 1 year are reported.
Treatment details
Induction for transplant was with basiliximab 10-20 mg (dose depending on body weight and general condition). In all patients, the CD25 level was checked on day 3, and the second dose of basiliximab was given only if CD25 was more than 3%. The second dose of basiliximab was given selectively in 15 patients.
In 54 patients, tacrolimus was used, and low-dose tacrolimus (level of 2-3 ng/ml) plus everolimus 0.25 mg twice a day was given in five patients. Mycophenolate mofetil was given to all patients. Steroids were given to all patients and tapered in 6 months in 45 patients and in the rest by 1 year.
Complications
In 38 patients, renal function normalized by day 5 allowing initiation of tacrolimus. In 12 patients, the renal recovery was delayed and tacrolimus could be started only on day 10 but without any side effects. Two patients needed therapy for azotemia with postoperative dialysis. Three patients died of severe renal failure and sepsis.
Fifteen patients had new-onset diarrhea in the 1 st year. Of these, four had CMV antigen positivity and this resolved with intravenous ganciclovir in three. One had Clostridium difficile-positive diarrhea which was treated with intravenous vancomycin and metronidazole. In seven patients, diarrhea resolved with termination of mycophenolate. Four had Escherichia coli or Salmonella diarrhea which responded to oral antibiotics.
One patient developed herpes zoster responding to acyclovir, and another developed hepatic mucormycosis responding to amphotericin.
Twelve patients, all above 40 years of age, developed sustained tremors which resolved with beta-blockers or vitamins. Five required changing from tacrolimus to cyclosporine. Ten had severe headaches needing tricyclic antidepressants and five needed a change to cyclosporine.
Ten patients had episodes of leukopenia, eight of which resolved after temporary stoppage of valganciclovir and reduced dose of mycophenolate and two patients needed granulocyte-colony stimulating factor therapy.
dIScuSSIon
This report covers the experience of 2 years and 55 patients. Mild side effects were noted in 30 patients after heart transplant. Side effects such as diarrhea, tremors, and headache were easily treated by clinical manipulation of drugs. Overall, 14 patients had significant bacterial or fungal or viral infections. Three patients died of sepsis (first 15 days after transplant in two patients and 3-6 months in another).
All patients received induction therapy with basiliximab ranging from 10 to 20 mg, and subsequent doses were based on CD25 counts. The use of basiliximab [2, 3] allows immunosuppression to start and also allows delayed calcineurin initiation when there is delayed renal recovery after a heart transplant. Using CD25 [4] counts helps adjust the basiliximab dose to minimize complications of infection posttransplant.
All patients received a triple regimen, [5] [6] [7] [8] [9] and steroids were tapered in 6-12 months in most of the patients. In most of the published series, 6-month and 1-year tapering has been found to be safe [10] though some transplant groups maintain on a very low dose of steroids.
Diarrhea was encountered and treated in 15 patients and was due to infections and drugs. In a study of more than 100 renal transplant patients with diarrhea for more than 7 days, diagnosis included bacterial infection (Campylobacter jejuni, Salmonella spp., and C. difficile), parasitic or protozoan infections, CMV infection, and other viral infections. [11] [12] [13] [14] Tremors and headaches were the common neurological complications which are similar to other series. [15] concluSIonS In 2 years, 55 patients underwent a transplant, and complications included infection and transient renal dysfunction. All patients received induction therapy and the triple immunosuppression regimen. Complications included diarrhea, tremors, and headache. Three patients died of sepsis.
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